OncoMatch/Clinical Trials/NCT06438627
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Is NCT06438627 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including TPC combined with Apatinib and Camrelizumab and GP Combined With Camrelizumab for nasopharyngeal carcinoma.
Treatment: TPC combined with Apatinib and Camrelizumab · GP Combined With Camrelizumab — This study aims to evaluate the efficacy and safety of the TPC regimen (nab-paclitaxel, cisplatin, and capecitabine) combined with apatinib and camrelizumab versus the GP regimen (gemcitabine and cisplatin) combined with camrelizumab for the treatment of high-risk regionally advanced nasopharyngeal carcinoma with a high risk of distant metastasis. The evaluation will be conducted through a prospective, controlled, open-label, multicenter phase 3 clinical trial in areas with high incidence of nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage TANYN3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
neutrophils ≥1.5×10^9/l, platelets ≥100×10^9/l, hemoglobin ≥90 g/l
Kidney function
creatinine <1.5 times the upper limit of normal
Liver function
transaminases <2.5 times the upper limit of normal, total bilirubin <1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06438627 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage TANYN3M0 is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages